In vitro fertilization has transformed reproductive medicine and sparked a number of therapeutic and diagnostic breakthroughs.
Now a new, still experimental, technique known as in vitro gametogenesis (IVG) is poised to usher in the next era in reproductive and regenerative medicine. The approach--thus far successful only in mice--allows scientists to create embryos in a lab by reprogramming any type of adult cell to become a sperm or egg cell.
In a newly published commentary, a trio of scholars argue that while IVG carries a promise to unravel the fundamental mechanisms of devastating genetic forms of infertility and to pave the way to a range of new therapies, the technique also raises a number of vexing legal and ethical questions that society should address before IVG becomes ready for prime-time clinical use in human patients.
The article, published Jan. 11 in Science Translational Medicine, is authored by I. Glenn Cohen, professor at Harvard Law School, George Q. Daley, dean of Harvard Medical School, and Eli Y. Adashi, professor of medical science and former dean of medicine and biological sciences at Brown University.
IVG holds enormous potential not only as a treatment for infertility, but also for a constellation of currently untreatable diseases, the authors write. Additionally, they note, the technique may provide an inexhaustible supply of lab-made embryonic stem cells for research and therapeutic use as a tantalizing alternative to scarce human embryonic stem cells, which are currently in limited supply due to ethical considerations and regulatory restrictions.
Yet, the authors say, such promises come with some worrisome scientific, legal and ethical challenges, such as the need for rigorous scientific protocols to ensure that any reproductive cells created through IVG are free of genetic aberrations, the threat of improper commercialization of IVG for large-scale embryonic generation and the use of preimplantation genetic screening to create "designer" offspring.
The authors acknowledge that clinical uses of IVG in the foreseeable future remain improbable at best. The impact of IVG, they say, will likely be limited to enhancing the science of germ cell biology. Yet, they caution, some clinical uses may arrive much sooner than anticipated, given the breakneck speed at which science and medicine are advancing.
To prepare for that time, scientists, bioethicists, policymakers, legal scholars and the public should initiate and maintain a vigorous conversation about the implications of IVG.
"Emerging technologies carry enormous promise but can also be profoundly disruptive. Aligning their promise with ethical and legal considerations is an imperative not only for scientists but for the society as a whole," said George Q. Daley, dean of Harvard Medical School. "To do so, we must initiate vital conversations early and engage the public. Nothing less will do on our quest to ensure that we strike the right balance between our most audacious scientific pursuits and our core ethical and legal principles."
The authors go on to say that the United States might be wise to borrow a page from the U.K.'s playbook, where a protocol focused on safety, ethics and public consultation has recently led to the launch of government-sponsored clinical studies of mitochondrial replacement therapy, a lab-based procedure that replaces defective mitochondrial DNA in a woman's egg cells with healthy DNA to avert passing the defects to her offspring.
"IVG has the potential to upend one of the most traditional elements of human culture--our understanding of what parenthood is and how it occurs," says Cohen, who is also the faculty director of thePetrie-Flom Center for Health Law Policy, Biotechnology and Bioethics at Harvard. "It is critical for law and medical ethics to grapple with the far-ranging implications of this new technology."
Scientific and therapeutic promise of IVG
- IVG could help scientists unravel the cellular and molecular aberrations responsible for DNA defects that cause a range of inherited diseases.
- The technology may be used as a fertility-salvaging strategy in prepubertal children who undergo cancer treatments that damage their immature reproductive organs and tissues.
- Certain inherited forms of infertility may become treatable by implanting healthy, genetically edited reproductive cells.
- The approach could prevent devastating mitochondrial diseases by creating egg cells, or oocytes, free of mitochondrial DNA defects.
- IVG may offer a safer alternative to traditional IVF treatments that require ovarian stimulation with injectable hormones, a procedure that carries a small but serious risk of harm.
Ethical perils, scientific challenges and legal considerations
- Current reprogramming technology used to coax adult cells into becoming multipurpose cells has advanced by leaps and bounds, but it may be far from foolproof, the authors argue. Therefore, perfecting existing techniques before any clinical use is critical to ensuring that both the original adult cells and the multipurpose cells they give rise to are free of genetic and epigenetic aberrations.
- Refining the science of IVG will, at least initially, require the generation and possible destruction of lab-made human embryos derived from stem cells. Under current U.S. law, such scientific pursuits would not be eligible for federal funding.
- IVG has the potential to rapidly and cheaply generate multiple embryos, which could reignite age-old concerns about "embryo farming" and commodification of human reproduction. How should regulators deal with that reality? Is the current federal and state scrutiny of sperm and egg banks an appropriate model?
- Widespread clinical use of IVG may also spark worries about human enhancement via preimplantation genetic diagnoses. The practice is already used with traditional in vitro fertilization to screen embryos for serious genetic defects. However, with a potentially unlimited supply of IVG-generated embryos, there may be concerns that some parents could select embryos for offspring based on preferred genetic traits unrelated to disease and health.
- Another potential concern is the prospect that IVG could enable direct gene modification via gene editing, which is now more feasible with emerging technologies like CRISPR. Hence, gene editing of germ cells could be practiced for genetic enhancement, raising considerable ethical concerns.
- IVG also increases the risk for unauthorized--or even surreptitious--use of biological material such as hair or skin cells to generate human embryos. That possibility is not only ethically troubling but also raises worrisome legal questions cutting to the very core of the legal definition of parenthood.
Harvard Medical School
Harvard Medical School has more than 9,500 full-time faculty working in 10 academic departments located at the School's Boston campus or in hospital-based clinical departments at 15 Harvard-affiliated teaching hospitals and research institutes: Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Cambridge Health Alliance, Dana-Farber Cancer Institute, Harvard Pilgrim Health Care Institute, Hebrew SeniorLife, Joslin Diabetes Center, Judge Baker Children's Center, Massachusetts Eye and Ear/Schepens Eye Research Institute, Massachusetts General Hospital, McLean Hospital, Mount Auburn Hospital, Spaulding Rehabilitation Network and VA Boston Healthcare System.
The Harvard Medical School Center for Bioethics
The Harvard Medical School Center for Bioethics was launched to ensure that values and ethics are always part of medical training, laboratory and clinical research, and professional education. The Center's mission is to bring together the rich intellectual resources of the medical school faculty with health professionals and scientists from our affiliated teaching hospitals, departments across Harvard, and colleagues from other institutions worldwide to ensure that scientific progress, medical therapeutics and health care practices proceed hand-in-hand with reflection about the profound moral questions raised by advances in the life sciences.
The Petrie-Flom Center for Health Law Policy, Biotechnology and Bioethics at Harvard Law School
The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School was founded in 2005 through a generous gift from Joseph H. Flom and the Carroll and Milton Petrie Foundation. The Center's founding mission was to promote interdisciplinary analysis and legal scholarship in these fields. Today, the Center has grown into a leading research program dedicated to the unbiased legal and ethical analysis of pressing questions facing health policymakers, medical professionals, patients, families, and others who influence and are influenced by health care and the health care system. To achieve this goal, the Center fosters a community of leading intellectuals, practitioners, and policymakers from a variety of backgrounds at all stages in their careers, across Harvard University and across the world.